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Abstract
Lung cancer (LC) is a heterogeneous disease consisting mainly of two subtypes, non-small cell lung cancer (NSCLC)
and small cell lung cancer (SCLC), and remains the leading cause of death worldwide. Despite recent advances in
therapies, the overall 5-year survival rate of LC remains less than 20%. The efficacy of current therapeutic
approaches is compromised by inherent or acquired drug-resistance and severe off-target effects. Therefore, the
identification and development of innovative and effective therapeutic approaches are critically desired for LC. The
development of RNA-mediated gene inhibition technologies was a turning point in the field of RNA biology. The
critical regulatory role of different RNAs in multiple cancer pathways makes them a rich source of targets and
innovative tools for developing anticancer therapies. The identification of antisense sequences, short interfering
RNAs (siRNAs), microRNAs (miRNAs or miRs), anti-miRs, and mRNA-based platforms holds great promise in
preclinical and early clinical evaluation against LC. In the last decade, RNA-based therapies have substantially
expanded and tested in clinical trials for multiple malignancies, including LC. This article describes the current
understanding of various aspects of RNA-based therapeutics, including modern platforms, modifications, and
combinations with chemo-/immunotherapies that have translational potential for LC therapies.
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Introduction
Lung cancer (LC) remains one of the primary causes of
cancer-related death in men and women globally [1]. In
2020, approximately 228,820 new cases and 135,720
deaths due to LC had been reported in the United States
alone [1]. LC is categorized into non-small cell lung can-
cer (NSCLC) and small cell lung cancer (SCLC). These
two main subtypes have prominent intra-tumor hetero-
geneity and are further classified based on mutations and
drivers [2, 3]. The majority of LC (~80-85%) fall in the
category of NSCLC that includes adenocarcinoma,
squamous cell carcinoma, and large cell carcinoma [4, 5].
Nearly 10-15% of cases belong to SCLC, categorizing into
SCLC-A, SCLC-N, SCLC-Y, and SCLC-P subtypes [6, 7].
The statistics of the last two decades showed that the 5-
year survival for NSCLC remains less than 20%, and for
SCLC, it is nearly 5% [1, 6, 8, 9]. Some of the routinely in-
vestigated oncogenes for targeting in NSCLC include
Kirsten rat sarcoma viral oncogene homolog (KRAS),
epidermal growth factor receptor (EGFR), and echino-
derm microtubule-associated protein-like 4-anaplastic
lymphoma kinase (EML4-ALK). Genes implicated in
SCLC include poly [ADP-ribose] polymerase (PARP),
delta-like protein 3 (DLL3), aurora kinases, and vascular
endothelial growth factor (VEGF) [10–13]. Approximately
30% of LC patients harbor activating KRAS mutations,
making it a potential drug target for LC therapy. However,
mutant KRAS targeting drugs have been under
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development for many years and are only now being
evaluated in clinical trials [8, 14]. Similarly, treatment with
tyrosine kinase inhibitors in the patients harboring EGFR
mutations has been relatively ineffective in improving the
overall survival (OS) [12, 15–18]. Similar gaps exist in
SCLC therapies: for example, most patients develop resist-
ance against chemotherapies, and due to the restricted
expression of receptor antigens (PD1/PD-L1), immunother-
apies show a narrow range of activity [19–23].
The major reason for the failure of currently available
therapeutic approaches is the development of drug re-
sistance associated with gene mutations, cancer stem
cells, overexpression of oncogenes, and deletion or in-
activation of tumor suppressor genes [10, 19, 24–28].
The collective outcomes suggested that the ‘tried-and-
true’ therapeutic regimen to save LC patients is lacking
and remains anticipated. To overcome these limitations,
there is a rapidly growing interest in the field of RNA
interference (RNAi) and RNA-based therapeutics, as sev-
eral studies have shown that silencing of specific genes
or overexpression of therapeutic proteins can serve as an
effective combination modality with chemo- or immuno-
therapy [29–37]. The last decade witnessed the
utilization of RNA therapeutics with chemotherapy and
immunotherapy and emerges as an active research hot-
spot for the development of different types of cancer
therapies [38]. The combination of adoptive cell transfer
(ACT) therapy with self-delivering RNA interference
(RNAi) was developed to down-regulate the expression
of checkpoint proteins by degrading the respective
mRNAs before their translation to proteins [39, 40].
These combinations also overcome drug resistance
and improve the efficacy of chemo-/immunotherapy
[39, 41]. RNA therapeutics can modulate multiple
pathways, including gene silencing and overexpres-
sion, manipulation of enzyme kinetics, sensitization,
and immune activation [37, 42, 43].
Additionally, advances in the field of noncoding RNAs
have established their role in normal cell physiology or
regulation of different molecular pathways, and studies
demonstrating the direct role of noncoding RNAs in
various pathologies have promoted the development of
RNA-based therapeutics [44–48]. The RNA therapy-
related studies suggested that these molecules have an
immense potential to regulate multiple cellular pathways
by inhibiting various genes [43, 49]. The ease of simul-
taneous targeting of multiple pathways provides an edge
to the RNA-based therapeutics platform to target the
different aspects of cancer such as tumor growth, metas-
tasis, and drug resistance [47, 48, 50–53].
The current cancer treatment modalities, including sur-
gery and chemotherapy, are far from ideal approaches, es-
pecially for the advanced stage tumors, as most of the
tumors exhibit mutational diversity [7, 54–56]. These
mutational heterogeneities play a significant role in cancer
progression, chemoresistance, and immune escape [54, 55,
57]. Thus, instead of conventional targeted therapies (that
include protein as a drug target), RNA-based treatment
strategies are potentially superior, as they have a diverse
target range with enhanced drug-like properties for cancer
therapies [38, 58]. Several approaches have been employed
to modulate gene-function at RNA level in the cancer
cells, including base editing, small molecules targeting
RNA, employment of synthetic antisense oligonucleotides
(ASOs), and exogenously expressed mRNAs [42, 43, 59].
The promise of RNA-based therapeutic modalities is
underscored by the successful outcomes of mRNA vaccine
approach in treating the disease caused by the SARS-
CoV-2 virus (COVID-19), and US Food & Drug Adminis-
tration (FDA) approval of Patisiran (first RNAi-based
treatment for hereditary transthyretin amyloidosis) and
Givosiran (RNAi-drug for acute intermittent porphyria),
and provide a strong rationale to explore RNA moieties as
a novel therapeutic strategy for cancer [37, 60–62]. The
recent advancements in terms of time, safety, pharmaco-
kinetics, and potency further provide support for explor-
ing RNA toolbox to develop potential anticancer
therapies. This review article surveys the classification, ap-
plications, and recent progress of RNA-based treatments,
including combination with first-line chemotherapy and
immunotherapy for LC field advancing RNAs as thera-
peutic agents, the available preclinical and clinical studies
with the future sequel to reach the patients.
Platforms for RNA based cancer therapeutics
RNA-based therapeutic strategies have emerged as an
alternative to the conventional protein-based therapies
that are difficult to pursue, as adapter proteins or
transcription factors. These types of protein molecules
can be regulated by modulating mRNA levels or transla-
tion of proteins [53, 63]. The primary focus of
oligonucleotide-based therapeutics includes gene silen-
cing or activation and splice modulation that provides
an extended range of potential targets beyond the con-
ventionally accessible pharmacological strategies. These
modalities follow the universal Watson–Crick base
pairing rule of complementarity, thus providing the dir-
ect interrogation of different putative target sequences.
Therefore, it is easy to rationalize, design, and screen-
specific leads if the primary sequence of the target gene
is available. To achieve the desirable functions (such as
gene silencing, splice modulation, transcript degradation,
translational activation, or antigen synthesis), different
oligonucleotide-based platforms, including antisense oli-
gonucleotides, RNA-interference molecules, and mRNA
transcripts, have been developed. We discuss each plat-
form in detail in the following sections.
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Antisense oligonucleotides
Antisense oligonucleotides (ASOs) are ~18-30 nucleo-
tide long, single-stranded, synthetic polymers of nucleic
acids with diverse chemistries [44, 64]. The ASOs are
small molecule drugs that target mRNAs based on com-
plementary base pairing and interfere with different as-
pects of gene expression and regulation. These
nucleotide sequences can interfere with DNA unwind-
ing, transcription, mRNA splicing, gene expression/
translational profile of target genes through different
mechanisms [38, 58, 65]. Based on their mechanism of
action the ASOs can be divided into two subcategories;
one-acts by promoting RNA cleavage and degradation
(either by ribonuclease H1 (RNase H1) or argonaute 2),
and the other is occupancy-only mediated regulation,
sometimes referred to as steric block (Fig. 1) [58, 64].
Binding of ASOs to the target RNA cleaves the target
at ASO binding site, facilitating the degradation of target
RNA and thus downregulating gene expression (Fig. 1).
This is one of the most widely used approaches for
downregulation of genes where overexpression is associ-
ated with the manifestation or progression of disease
[58, 66]. RNase H1 is a highly selective endonuclease
that specifically acts on the RNA of the RNA-DNA het-
eroduplex [58, 67, 68]. The detailed enzymatic and cellu-
lar functions of RNase H1 have been uncovered now,
and the substrate specificity of RNase H1 is continuously
utilized for the development of RNA-based therapeutics
[43, 44, 68, 69]. In mammalian cells, the distribution of
RNase H1 is ubiquitous and found in the cytoplasm,
mitochondria, and nucleus [69, 70]. It serves various
genomic functions, including DNA repair, resolution of
R-loops, removal of pre-mRNAs associated with chro-
matin, transcriptional termination, maintenance of gen-
ome integrity, and removal of Okazaki fragment-
associated RNA [44, 69–74]. Interestingly, the ASOs de-
signed to utilize endonuclease activity as the mechanism
of their action must possess a stretch of at least five
DNA-nucleotides. Thus, currently used ASOs that fol-
low RNase H-competent mechanisms are based on the
patterns of DNA ‘gapmer’, a hybrid type of oligonucleo-
tide sequence where the central stretch of DNA known
as ‘gap’ is inserted between chemically modified RNA
flanking sequences (that helps in target binding), Fig. 1.
The main advantage of using RNase H1 based ASOs is
that it makes the targeting of nuclear transcripts (for ex-
ample, pre-mRNAs and long non-coding RNAs) easy.
These are less accessible to other approaches like small
interfering RNA (siRNA) [58].
Steric block or occupancy-only mediated mechanism
utilizes high-affinity ASOs to bind with the target RNA
without inducing the direct degradation of target RNA
[66, 75] (Fig. 1). This class of ASOs consists of nucleo-
tides that do not form RNA-DNA duplex, which acts as
a substrate for RNase H1 or Ago2. Therefore, to avoid
the formation of RNase H substrates and unwanted
cleavage of target RNA, the ASOs must be modified
chemically or comprises of a mixture of different nucleo-
tide chemistries, generally called ‘mixmers’ in such a way
that stretches of consecutive DNA-like nucleotides can
be avoided [64, 75]. Some common chemical modifica-
tions include thiophosphoroamidate, thiophosphoroami-
date morpholinos, nucleoside moieties, and peptide
nucleic acid attachments (Fig. 2) [76, 77]. Steric block
ASOs bind with the specific sequence of target and work
by modulating the translation, processing of RNA, spli-
cing, RNA-protein interactions, and interactome of
target RNA [65, 78, 79]. The most common application
of these ASOs is to manage the selective exclusion or
inclusion of exon(s) through the modulation of alterna-
tive splicing (for example, exon skipping and inclusion),
Fig. 1 [80–82]. Interestingly, the ASOs steric block ap-
proach can be used for corrupting the target splice vari-
ant, where the exon skipping method hinders or
downregulates the translation of the target transcript
(Fig. 1) [83, 84]. The splice correction/inclusion ap-
proach has been used to correct or restore the transla-
tional frame to rescue the synthesis of therapeutic
proteins [81, 85–89]. The ASOs perform this function
by masking the splicing signals, making target invisible
to the spliceosome, and finally alter the spliceosome’s
splicing decisions [58, 81, 90].
Earlier, the antisense approaches were mainly used to
downregulate the gene expression or translation, but not
broadly as an alternative for the situations where the
overexpression of beneficial proteins was required as a
therapeutic strategy. More recently, the combinatorial
investigation of several approaches like ASOs, micro-/si-
RNAs to increase the target RNA expression or protein
translation has revolutionized the RNA-based thera-
peutic strategies for different diseases, including cancer
[44, 46, 65]. Further studies have established the
utilization of ASOs for the targeting of microRNAs, and
ultimately an efficient approach to enhance protein pro-
duction (Fig. 1) [65, 79, 91, 92]. The microRNAs (short
RNAs consisting of 21-23 nucleotides) inhibit the gene
expression or protein translation and control associated
gene networks. These observations have inspired the de-
velopment of ASOs targeting microRNAs that block or
repress their binding properties with target RNA tran-
scripts, resulting in the translational escalation of
microRNA-regulated genes (Fig. 1) [65, 79]. As micro-
RNAs possess cell- or tissue-specific activities to inhibit
the translation of multiple RNAs or targets, blocking of
a single microRNA can alter the expression of different
proteins. Alternatively, the utilization of specific ASOs
against 5`-untranslated regions of mRNAs (that gener-
ally represses translation through upstream open reading
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frames or stem-loop structures) is a more precise and
targeted approach to increase the protein production of
associated RNA targets [44, 65, 79]. Alternative splicing
is a beneficial strategy for generating protein diversity.
ASOs can be utilized to induce isoform switching for
promoting the expression of therapeutic/beneficial pro-
teins and/or inhibiting the expression of disease-
associated proteins (Fig. 1). Based on these mechanisms,
three ASOs have received FDA approval for splice-
switching: golodirsen, usinersen, and eteplirsen [58].
RNA interference
The seminal paper published by Andrew Fire and Craig
C. Mello in 1998 suggested the role of double-stranded
RNAs in post-transcriptional gene silencing through a
mechanism known as RNA interference (RNAi) and rev-
olutionized the field of gene silencing [93]. This study
contributed to the understanding of gene silencing and/
or expression-related puzzles in fungi and plants and hit
out the field by establishing the central role of non-
coding RNAs in gene expression. Later, two independent
Fig. 1 Different mechanisms of action for antisense oligonucleotide mediated gene silencing. Based on post-hybridization events, antisense
oligonucleotides can modulate the expression of target gene through two different mechanisms 1) Occupancy-only mechanisms 2) RNA
degradation mechanisms. In occupancy-only mechanisms, ASOs binding with target RNAs does not result in RNA degradation. It modulates the
gene expression in several ways: splicing modulation using splice switch ASOs to perform exon-skipping or exon inclusion; inhibition of mRNA
polyadenylation; translational modulation through non-DNA-like ASOs that base pair with mRNA, either to inhibit translation, for example, steric
blocks or to activate translation by binding to inhibitory elements like upstream open reading frames (uORF). For the inhibition of miRNA-related
function, these ASOs can also modulate miRNA either by base pairing with miRNA (anti-miRs) or by occupying miRNA-responsive elements (MRE)
on target mRNA to nullify the effect of a particular miRNA. On the other hand, the ASOs in RNA degradation pathways trigger the target mRNA
cleavage either by RNase H1 or siRNA-mediated AGO2 RISC complex and ribozymes mediated cleavage
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studies from Elbashir et al., [94] and Caplen et al., [95]
reported that small size double-stranded RNAs (approxi-
mately 19-22 nucleotides in length) having sequence
homology to the silenced gene are the key mediators of
sequence-specific post-transcriptional gene silencing in
animals and plants. These small/short interfering RNAs
(siRNAs) are processed from longer dsRNAs by ribo-
nuclease III and maintain a characteristic structure (with
5'-phosphate/3'-hydroxyl ends) with a 2-nucleotide 3'-
overhang on each duplex strand [94, 95]. These studies
established that the siRNA molecule induces RNAi in
mammalian cells without undesired interferon responses
and is now accepted as a simplistic universal biological
tool for gene silencing studies. RNAi is a mechanism
used by the cells to downregulate gene expression in
genetic abnormalities and infections [38]. Hence, RNAi
Fig. 2 Common chemical modifications in antisense oligonucleotides and RNA oligonucleotides. Different types of RNA modifications or RNA
analogs have been identified and evaluated in antisense mechanisms. A representative structure of dinucleotide is shown with marked positions
where oligonucleotides are commonly modified. Commonly used modifications in ASOs consist of sugar modifications, base modifications,
phosphate modifications, internucleoside linkage modifications, and conjugates of small or large molecules (as shown in the upper panel). Along
with the structural modifications, the therapeutic properties of several key modifications are also highlighted. Specific internal RNA modifications
are shown in the lower panel of figure (uridine-to-pseudo uridine and adenosine to-inosine transition are also presented). cEt BNA: (S)-
constrained ethyl bicyclic nucleic acid
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approaches were explored and adapted as a potential
therapeutic strategy for treating different diseases, in-
cluding cancer [38, 47, 96–98].
The potency, flexibility, and diversity of the RNAi or
siRNA approach are alluring for prospective drug devel-
opment targeting proteins that remain undruggable
through classical approaches of small molecule inhibi-
tors [99–101]. RNAi-mediated therapeutic approaches
silence genes by utilizing the natural machinery of the
targeted cells. These approaches include siRNAs, small
hairpin RNAs (shRNAs), microRNAs (miRNAs), long
double-stranded RNAs processed through Dicer, and
small specific sequences synthesized to meet the RNAi
criterion. Double-stranded siRNAs (ds siRNA) are pro-
drugs-like molecules consisting of the complementary
duplex of sense and antisense strand. Interestingly, the
sense strand (passenger strand) of siRNA formally satis-
fies the definition of drug delivery vehicle; it is non-
covalently associated with antisense or the guide strand
that is complementary to the target RNA/transcript, pro-
tects it from degradation and helps in the loading of
antisense strand to Ago2 (Fig. 3) [101, 102]. After load-
ing to Ago2, the sense strand is removed before per-
forming the pharmacological activity. The antisense
strand guides the Ago2-mediated RNA-induced silen-
cing complex (RISC) to the target site, and the complete
complementarity of siRNA with the target leads to the
cleavage (known as slicer activity) and silences gene ex-
pression (Fig. 3) [102–105]. Ago2 is an RNA endonucle-
ase with RNase H domains, but unlike RNase H1, it
cleaves RNA in RNA-RNA duplex (not DNA-RNA du-
plex) [106]. Ago2 complex plays an important role in fa-
cilitating the binding of antisense strand to the target
transcript, and thus, Ago2 has become a key regulator
for efficient RNA-based pharmacological mechanisms
with different features [102, 107]. The loading of siRNA
or specifically antisense strand into Ago2 is a very effi-
cient process, but for effective binding and cleavage ac-
tivities, Ago2 has some strict structural requirements
[108]. For example, availability of 5'-phosphate or phos-
phate analog and comparatively fewer modifications
were allowed at 2' site, located at the distal site of seed
sequence (nucleotide sequence that recognizes RNA tar-
geting site) [64, 109].
Ago2 also prolongs the duration of action as once
the antisense strand is loaded, it retains the strand
for a more extended period [107, 110]. The
localization of Ago2 is cytoplasmic; hence, siRNAs
are used as prominent tools for targeting cytoplasmic
RNAs (Fig. 3) [64, 102]. Studies suggest that some
modifications in conventional siRNA sequences or
designs can improve the pharmacological benefits
like enhanced potency and reduced off-targeting.
Few examples of atypical siRNAs include single-
stranded RNAs [111, 112], divalent siRNAs [113],
self-delivering siRNAs [114], small internally seg-
mented siRNAs [115], and Dicer substrate siRNAs
[116]. The outcomes of RNAi studies recently led to
the FDA approval of two siRNA based therapeutics
named Patisiran and Givosiran [61, 62].
MicroRNAs
MicroRNAs (miRNAs or miRs) are short non-coding
RNAs that trigger endogenous RNAi by regulating the
stability or inducing mRNA degradation. The miRNAs
have diverse role in various physiological and patho-
physiological progressions, including cell-cycle progres-
sion [117], cancer development and progression [118–
120], metabolism [121], diabetes [122], infectious dis-
eases [123, 124], muscular dystrophy [125], and immun-
ity [126]. Therefore, miRNAs are an important class of
putative drug targets. The biogenesis of miRNAs follows
a systematic process; the initial or primary miRNA
strand is transcribed in the nucleus (Fig. 3) [127, 128].
The miRNA hairpin structure, embedded within the pri-
mary miRNA strand, is sequentially processed by
DROSHA and DICER (both belong to the RNase III
family) and finally emerges as a mature miRNA consist-
ing of 21-22 nucleotides [127, 128]. Mature miRNA se-
quence is then loaded to the RISC complex and
modulates gene expression by binding with the 3'-un-
translated region (UTR) of the target gene (Fig. 3). The
inhibition of gene expression is directly dependent on
miRNA’s complementarity to that of target mRNA [38].
In addition to the inhibition of gene expression, miRNAs
also modulate transcriptional regulation. Recent studies
showed that miRNAs regulate the methylation of CpG
islands in the promoter region of different genes and,
thus, directly regulate the transcriptional regulations
through epigenetic modifications [129–132]. The pri-
mary mode of action for miRNA and siRNA is similar,
as both form RISC complex for targeted gene silencing
(Fig. 3). The main difference is that siRNAs degraded or
inhibited mRNA translation with 100% complementarity
and thus precisely follow target specificity. In contrast,
miRNAs usually bind with incomplete complementarity
and perform gene silencing through slicer-independent
pathways. The miRNAs target 3'-UTR of mRNA and
suppress the gene expression or decrease its stability. Be-
cause miRNAs can act through low complementarity;
thus, they could have multiple targets, but the primary
safety check is the restriction of imperfect base pairing;
otherwise, one miRNA can affect thousands of genes.
Interestingly, the ASOs have also been developed and
employed for miRNA inhibition through direct binding to
the small RNA molecules in the RISC complex, and these
ASOs are known as antagomirs or anti-miRs (Fig. 1)
[133–135]. Miravirsen (also known as SPC3649) was the
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first anti-miRNA drug designed to treat chronic hepatitis
C virus (HCV), and it targets the activity of liver-specific
miR-122 [136]. The 5'-UTR of HCV RNA consists of two
binding sites for miR-122, which stabilizes the viral RNA
[137, 138]. Miravirsen inhibits this binding by sequestering
miR-122, making it readily available for exonuclease deg-
radation, decreases replication, and thus reduces the viral
load [139, 140]. However, viral recovery in patient serum
and resistance to Miravirsen was observed, along with the
development of new mutations [140, 141]. Similarly, an-
other anti-miR drug, RG-101, was designed (by Regulus
Therapeutics) against miR-122 and used to control HCV
infections but failed to improve overall outcomes in clin-
ical trials [142]. Similarly, RG-101 induced viral rebound,
along with the substitutions in the binding regions of
miR-122 (in the 5' UTR of the HCV genome) and
developed resistance [142]. Outcomes of another clinical
trial suggested that treatment with RG-101 restores the
natural killer (NK) cell population that controls HCV in-
fection [143]. A recent clinical trial suggested the potential
of a combination regimen of RG-101 and GSK2878175 (a
non-nucleoside NS5B polymerase inhibitor) to develop a
single-visit cure for HCV patients [144].
Several groups are also developing anti-miR drugs
against miR-21, miR-17, miR-155, and miR-29 for
cancer, kidney, and other diseases [58, 145–148].
These miRNAs (especially miR-21) have a diverse role
in lung cancer establishment, progression, and metas-
tasis, so these anti-miRs can also be utilized as an ef-
fective therapy for lung cancer. Steric block ASOs are
also being developed to target specific miRNAs. These
oligonucleotides obstruct the regulatory interactions
Fig. 3 Schematic illustrations for siRNA/miRNA biogenesis and, the mRNA inhibition via siRNA and miRNA-mediated mechanisms
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of miRNAs with target mRNA (Fig. 1), thus providing
an important strategy to downregulate the activity of
diseases specific miRNAs [149]. The details of related
reports and implications of anti-miRs/ASOs in lung
cancer therapies are discussed in forthcoming
sections.
mRNA platforms
The fundamental step of the central dogma of molecular
biology is that mRNA carries the information from DNA
and transfer to the protein synthesis factories [150]. Pro-
tein molecules are the ‘workhorses’ of the body as nearly
every function (normal and disease-related) of the hu-
man body is performed by different proteins [151]. Inter-
estingly, the mRNA is equally critical as DNA because
the human body would never utilize the genetic code if
mRNA is not available, or proteins will never be synthe-
sized. Besides, normal physiological functioning of the
human body, downregulation of therapeutic proteins or
upregulation of diseases associated proteins, and entry of
foreign proteins lead to the disease condition [151, 152].
The important functional role associated with different
proteins ultimately clues towards the development of
protein-targeted drugs or therapies.
Due to several difficulties in protein targeting, re-
searchers moved to DNA-based gene therapy. However,
the stumpy likelihood of genome integration and transi-
ent nature makes it challenging to use in the clinics
[153–155]. On the other hand, mRNA is a molecule that
overcomes these two major pitfalls (targeting and gen-
ome integration) and has emerged as a strong alternative
to conventional gene therapy strategies [153, 155–157].
Additionally, it uses natural or homegrown cell machin-
ery for protein synthesis that return properly folded ma-
ture therapeutic protein with all post-translational
modifications, thus providing better opportunities over
recombinant proteins [157]. The treatment strategies
based on mRNA therapies involve the implications of
specific mRNA sequences into the patient’s body and
utilization of cellular machinery to synthesize specific
proteins involved in the disease progression. This
method is applicable in multiple conditions, as it can be
used to overexpress specific proteins whose downregula-
tion is associated with disease and could be used to elicit
an antigenic response by inducing the expression of spe-
cific antigens [37, 51, 158].
However, initial studies suggested that in-vitro tran-
scribed/synthesized mRNA molecules are less stable as
they are readily accessible to nucleases and easily detected
by toll-like receptors (TLRs) and activate dendritic cells
(DCs) that generate innate immune response [159–161].
To understand the immunogenic responses associated
with synthetic mRNAs, researchers have incorporated sev-
eral modifications in RNA nucleosides [162–164]. A very
interesting study by Kariko et al. showed that modification
of mammalian RNA nucleosides (for example, 5-
methylcytidine, N6-methyladenosine, 5-methyluracil,
pseudouridine, and N7-methylguanosine) decreases the
immunomodulatory signals and DCs exposed to these
modified mRNAs reduced activation and cytokine produc-
tion compared to DCs exposed to unmodified RNAs
[165]. This is also a defense mechanism utilized by innate
immune response of the human body to bacterial or other
foreign non-mammalian RNAs. These organisms have less
abundance of modified nucleosides that potentially acti-
vate TLRs expressing cells and DCs [165]. Thus, modifica-
tions in nucleosides overcome RNA-mediated activation
of DCs. This approach can potentially affect the design
and development of mRNA-based therapies.
Following their synthesis, RNA molecules can
undergo more than 150 different chemical modifica-
tions in the cells that impact their stability, distribu-
tion, and other post-transcriptional events;
collectively, these modifications are known as ‘epitran-
scriptome’ or RNA epigenetic modifications [166–
169]. Some of the common modified mRNA nucleo-
sides are N6-methyladenosine (m6A), 5-
methylcytidine (m5C), N7-methylguanosine (m7G),
pseudouridine (s2U), inosine, and many 2′-O-methyl-
ated nucleosides (a part of the 5′-terminal cap), as
shown in Fig. 2. Each chemical modification plays a
specific role like, m6A enhances mRNA turnover, reg-
ulates embryonic stem cell development, favors RNA
decay, pre-mRNA splicing, adipogenesis, and prostate
cancer bone metastasis [170–174]. Similarly, s2U reg-
ulates the structure of RNA, increases stability, and
alters translational efficiency [175, 176], while m5C
induces codon rewiring and, in combination with
other modifications, guides miRNA targeting [166,
177]. For translation, ribosomes scan mRNA tran-
scripts at the 5′ UTR within Kozak sequences to
identify start codon, but the length of 5′ UTR, pres-
ence of cis-elements, and m6A modulate ribosome
scanning and finally regulate the translational effi-
ciency [172, 178, 179]. Interestingly, some transcripts
that retain m6A in their 5' UTR can be translated in
a 5′ cap-independent manner due to the direct bind-
ing of 5' UTR m6A with the eukaryotic initiation fac-
tor 3 (eIF3), which alone is enough to recruit the 43S
ribosomal complex and initiate translation [180]. In-
hibition of N6-methylation in adenosine specifically
decreases the translation of mRNA transcripts con-
sisting 5'UTR m6A. The cap-independent translation
mechanism was studied for heat shock protein 70
(Hsp70) mRNA, and it was observed that cellular
stress induces a global rearrangement of m6A in the
transcriptome Hsp70, making more mRNAs with
m6A in the 5' UTR [180, 181]. Thus, m6A in 5' UTR
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helps translate the mRNA under stress conditions
through bypassing the dependency of 5' cap-binding
proteins and suggests that such RNA modifications
can be incorporated while designing and optimizing
therapeutic RNAs/mRNAs.
With the diverse applications of RNA-based therapies
and the potential to translate into clinics, synthetic
mRNAs have emerged as a powerful tool and alternative
to conventional therapies/vaccines. In recent years, sig-
nificant advancement has been achieved to develop
mRNA-based therapeutics for immune-oncology, pro-
tein replacement therapies, and vaccine development
[37, 60, 182]. Indeed, mRNA-based vaccine formulations
developed by Pfizer and Moderna were developed and
approved in record time to combat coronavirus disease
2019 (COVID-19) caused by the global outbreak of se-
vere acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) [182–184]. The successful safety and efficacy
outcomes of these vaccines are likely to enhance the
enthusiasm and trust, and likely to dictate the future
course of RNA-based therapeutics in general. Based on
recent mRNA-based cancer vaccine studies in melanoma
[51] and other infections like COVID-19 mRNA-based
vaccine, the developmental route map for the mRNA-
based LC vaccines is outlined in Fig. 4.
Implications of RNA-based platforms in LC
ASOs in LC therapy
The ASOs have broad applications for different antican-
cer therapies, including LC. The implications of anti-
angiogenic therapies for lung squamous cell carcinoma
are limited and associated with adverse side effects
[185–187]. Recent evidences established the role of long
noncoding RNAs in tumor progression and VEGF
modulation that guide the potential of RNA-based ther-
apies for the development of anti-angiogenic strategies
for LC [188–195]. Overexpression of LINC00173.v1 was
associated with proliferation, tumorigenesis, migration of
Fig. 4 Schematic illustrations for mRNA-based LC vaccine development. The aim of mRNA vaccine development was started with a comparative
analysis of exome of LC tissue and normal tissue to identify potential tumor-specific antigen(s). The detailed analysis coupled with high
throughput methods enables the verification of identified antigen(s)/neoantigen(s) specific to LC. The mRNA sequence(s) specific to tumor
antigens will then be synthesized, modified, and cloned into appropriate plasmids for the mRNA transcription. The liposome formulations (or
other appropriate vehicles) of the final, optimized mRNA(s) encoding LC-specific antigens will be injected into LC patients to elicit a prominent
anticancer immune response for the destruction of LC tumors
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vascular endothelial cells, and poor overall survival in
squamous cell carcinoma patients [196]. LINC000173.v1
upregulates the expression of VEGFA through miR-511-
5p sponging and inhibition of LINC000173.v1 using
ASOs resulted in decreased tumor growth and enhanced
cisplatin sensitivity [196].
A recent study demonstrated the potential of ASOs to
downregulate the expression of metadherin, which plays
a role in T cell exhaustion and WNT signaling [197].
Downregulation of metadherin in cell lines and spontan-
eous mouse models using locked nucleic acid (LNA)
modified ASOs significantly decreased LC progression
and metastasis [197]. Similarly, miR-21 is among the top
differentially upregulated microRNAs in NSCLC and
regulates cell growth, proliferation, migration, invasion,
apoptosis, and drug resistance [198–202]. Ge et al. re-
cently reported the use of phosphorothioate ASOs to in-
hibit miR-21 expression and found that these ASOs
decrease the proliferation of NSCLC cells and induce
apoptosis through caspase-8 pathway activation [198].
KRAS is a frequently mutated gene in different can-
cers, and activating mutations in KRAS are observed in
20% of human tumors, including NSCLC [54, 203–206].
KRAS is a highly desirable target for cancer therapy;
however, the development of pharmacological small
molecules for mutant KRAS remains challenging, and
most of the identified inhibitors are still in early-stage
clinical trials [14, 205–207]. AZD4785 is a high-affinity
KRAS mRNA-targeting therapeutic ASO that selectively
decreases mutant KRAS mRNA as well as protein. Un-
like the inhibitors of RAS-MAPK pathways, this deple-
tion did not activate the feedback loop of the MAPK
pathway. AZD4785 downregulated the effector pathways
and selectively decreased the proliferation of cells har-
boring mutant KRAS [208]. The systemic injection of
AZD4785 to NSCLC mice xenografts and patient-
derived xenografts harboring mutant KRAS inhibited
KRAS expression and induced strong antitumor activity.
This suggested that AZD4785 and other novel ASOs are
innovative therapeutic approaches for treating KRAS-
and other mutated oncogenes.
Wang et al. reported the construction of novel poly-
ethylene glycol (PEG) ligated antisense therapeutic oligo-
nucleotides that form a bottlebrush-like structure
consisting of PEG side chains, DNA backbone, and over-
hangs of antisense oligonucleotides [209]. These formu-
lations possess PEG at high density on the surface,
which decreases the undesired interactions of ASOs with
DNA and proteins (protecting from enzymatic degrad-
ation) and enhances the chances of antisense overhangs
to hybridize with target mRNA, thereby reduce protein
expression. This study evaluated KRAS targeting by
these PEGylated ASOs in lung cancer. These modified
ASOs had higher inhibition efficacies than conventional
hairpins, and the antisense molecules decreased the pro-
liferation of LC cell line expressing mutant KRAS
(G12C) gene [209]. These ASOs showed enhanced
in vivo retention time (due to high biological compatibil-
ity of PEG) and represent an important strategy to im-
prove biopharmaceutical efficacies and translational
applicability of ASOs mediated therapies.
ADP-ribosylation factor like 4C (ARL4C), a member
of small GTP-binding protein family, is frequently over-
expressed in adenomatous hyperplasic lesions (precur-
sors to adenocarcinoma) and lung cancer [210]. ARL4C
promotes cell proliferation and is a potential therapeutic
target for lung cancer [211–213]. ARL4C expression is
directly correlated with different histologic stages
(adenocarcinoma, minimally invasive adenocarcinoma,
and invasive adenocarcinoma) and is associated with a
poor prognosis. ASOs targeting ARL4C (ASO-1316)
showed decreased RAS-related substrate activity, inhib-
ited cell proliferation and migration, and suppressed nu-
clear import of Yes-associated protein-1 (YAP-1) in lung
cancer cell lines bearing KRAS and EGFR mutations. In
addition, ASO-1316 reduced tumorigenicity of KRAS/
EGFR mutated lung cancer cell lines in orthotopic mice
models [210]. This study established the role of ARL4C
in the initiation of premalignant lesions, tumor progres-
sion and development, and demonstrated the utility of
ASO-1316 as a potential therapeutic agent for LC pa-
tients with ARL4C overexpression, regardless of muta-
tion status.
A recent study demonstrated that ASOs attached with
deoxyadenosine (dA40) can form complex with β-glucan
schizophyllan (SPG) [214], and ASOs-dA40/SPG com-
plex can be recognized by Dectin-1 (a β-glucan receptor)
expressed on lung cancer cells and antigen-presenting
cells (APCs) [215, 216]. ASOs-dA40/SPG targeting KRAS
inhibited KRAS expression in Dectin-1 expressing LC
cells and correspondingly decreased cell growth. This
ASOs-dA40/SPG complex enhanced the cytotoxic effect
of gemcitabine due to the ability of dA40 moiety to
directly interact with gemcitabine. Interestingly, after in-
ternalization, this interaction dissociates, and gemcita-
bine is easily released from the complex [214]. It means
that conjugation of SPG and dA40 bearing ASOs can
also serve as potential carriers for gemcitabine and other
structurally similar drugs. Due to this dual ability of
ASOs-dA40/SPG complexes to target KRAS and
enhance gemcitabine efficacy, it will be of interest to
evaluate these formulations in clinical trials.
Signal transducer and activator of transcription 3
(STAT3) is a central molecule for oncogenic/non-onco-
genic signaling. STAT3 overexpression is associated with
the progression of various cancers, including LC, making
it a potential target for cancer therapy [217]. AZD9150,
an advanced ASO consisting of ethyl-modifications, was
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designed to target STAT3 as it is challenging to target
transcription factors through small molecule inhibitors
[218]. Preclinical evaluations demonstrated that
AZD9150 decreased the expression of STAT3 and ex-
hibited prominent antitumor effects in several preclinical
cancer models of lymphoma and LC. In a phase I clinical
trial (NCT01563302) for diffuse large B-cell lymphoma
(DL-BCL) AZD9150 was well tolerated and exhibited ef-
ficacy in a subset of heavily pre-treated patients [219].
Currently, combination studies of AZD9150 with im-
mune checkpoint inhibitors are in progress. Therapeutic
silencing of STAT3 can also be achieved by targeting
STAT3 binding to target sites. CS3D is a cyclic 15-mer
oligonucleotides decoy corresponding to the response
element of STAT3 target genes [220]. The CS3D decoy
was tested on EGFR inhibitor-resistant NSCLC cells and
resulted in the downregulation of STAT3 targeted c-
MYC gene at mRNA and protein levels. Further, CS3D
inhibited cell proliferation, colonization and, increases
apoptosis in vitro, and reduced tumor growth along with
c-MYC expression in vivo [220]. Thus, targeting of
STAT3 with RNA-based oligonucleotides is a promising
alternative for small molecules chemical inhibitors to de-
velop effective therapies for LC.
High expression of Bcl2 and Akt1 promotes the
growth, proliferation, and apoptotic evasion in LC, and
Bcl2 is a potential therapeutic target for both NSCLC
and SCLC [221–223]. G3139 and RX-0201 are ASOs
that target Bcl2 and Akt-1, respectively, but have exhib-
ited limited efficacy in clinical trials due to inadequate
delivery. These ASOs were modified using the ‘Gapmer’
strategy and 2'-O-methyl modifications at 5' and 3' ends.
To enhance the targeting and delivery, cancer cell-
specific lipid nanoparticles (conjugated with transferrin
receptor-targeting T7 peptide) were synthesized with
these modified ASOs [224]. The ASO co-loaded nano-
particles exhibited enhanced colloidal stability, high en-
capsulation with smaller particle size, and higher cellular
uptake. The T7-ASO-lipid nanoparticles decreased the
expression of Bcl2 and Akt-1in LC cell lines, exhibited
superior antitumor effects, and improved the overall sur-
vival (OS) in LC xenograft bearing mice [224]. The
in vitro activity of gapmer based G3139 ASO lipid nano-
particles for Bcl2 was also evaluated [225]. The G3139-
GAP (with 2'-O-methyl nucleotides) was incorporated
into DOTAP/egg PC/cholesterol/Tween 80 lipid nano-
particles, and anticancer efficacy was studied in A549
cells and xenograft mouse models. These gapmer based
ASOs lipid nanoparticles reduced the Bcl2 expression at
mRNA as well as protein level in cell lines and tumors,
and inhibited tumor growth, and improved OS [225].
Self-renewing tumor-initiating cells (TICs) or cancer
stem cells mainly contribute towards tumor initiation,
recurrence, and treatment resistance [226–228]. The
overexpression and activity of glycine decarboxylase
(GLDC) maintain TICs and is possibly responsible for
tumorigenesis of NSCLC [229]. GLDC is a key member
of the glycine and serine metabolic pathway, regulating
pyrimidine metabolism and cancer cell proliferation. No
therapeutic molecule is available for GLDC; hence ASOs
could be a novel strategy to downregulate GLDC [230].
The splice-modulating steric-block ASOs were designed
to induce exon-skipping to disrupt the open reading
frame of GLDC encoding transcripts and induce
nonsense-mediated degradation. These GLDC steric
blocks inhibited cell proliferation and colonization of LC
cell lines, and NSCLC TICs derived tumor-spheres. The
candidate GLDC ASOs decreased the tumor growth of
TICs derived xenografts in mice [230]. Overall, these re-
ports suggested that ASOs hold strong promise to de-
sign and develop RNA-based therapeutic regimens for
LC.
RNAi therapies in LC
RNAi moieties (siRNAs and miRNAs) effectively silence
target genes by inducing mRNA degradation or inhibit-
ing the binding sites of translational machinery (Figs. 1
& 3) [8, 38]. Cyclooxygenase-2 (COX-2) is an important
drug target in LC that regulates cancer progression, me-
tastasis, metabolism, and tumor immunity [231–234].
However, the available COX-2 inhibitors have failed to
show clinical efficacy. Instead of direct COX-2 inhib-
ition, knockdown of delta-5-desaturase (D5D) offers a
unique approach that limits the formation of arachidonic
acid (a substrate for COX-2) and promotes the peroxida-
tion of dihomo-γ-linolenic acid leading the production
of 8-hydroxyoctanoic acid (8-HOA) [235]. Pang et al. in-
corporated the siRNA of D5D with epithelial cell adhe-
sion molecule (EpCAM) aptamers into three-way
junction RNA nanoparticles that exhibited target specific
accumulation, D5D knockdown, and formation of 8-
HOA in lung cancer cell lines and mouse models [236].
These D5D siRNA-loaded nanoparticles inhibited the
proliferation of lung cancer cells and induce apoptosis
by suppressing YAP1/TAZ axis.
Single nucleotide polymorphism (SNPs) and lncRNAs
play a prominent role in LC [237–239]. Analysis of LC
risk-associated SNPs and lncRNAs, identified an oxida-
tive stress-responsive serine-rich 1 antisense RNA1
(OSER-AS1) as a prognostic biomarker and therapeutic
target [240]. Downregulation of OSER1-AS1 in tumor
tissues was associated with poor OS in NSCLC patients.
Myc represses the promoter of OSER-AS1, which is also
targeted by RNA binding protein ELAVL (embryonic le-
thal, abnormal vision, Drosophila)-like 1 (ELAVL1) and
hsa-miR-17-5p at the 3'-end. OSER1-AS1 acted as a
decoy for ELAVL1 and inhibited its interaction with tar-
get mRNA. Treatment with OSER1-AS1 resulted in the
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inhibition of growth and metastasis of xenograft LC
tumors.
Two independent studies performed on lncRNA nico-
tinamide nucleotide transhydrogenase-antisense RNA1
(NNT-AS1) showed that overexpression of NNT-AS1 is
correlated with poor prognosis of NSCLC [241, 242].
NNT-AS1 upregulation decreases miR-22 by sponging
and is associated with increased expression of FOXM1
and YAP-1. Knockdown of NNT-AS1 attenuates cell
proliferation, invasion, migration, induces apoptosis, and
suppresses in vivo tumor growth. Further, NNT-AS1
contributes to drug resistance in NSCLC through
MAPK-slug signaling [243]. Thus, NNT-AS1 is a poten-
tial RNA-based therapeutic target and prognostic marker
for NSCLC. Wanjun et al., reported the analysis of non-
canonical small non-coding RNAs (sncRNAs) using per-
ipheral blood mononuclear cells of human and identify a
unique ‘disease RNA code’ named TRY-RNA signature
composed of distinct tRNA-derived small RNAs
(tsRNAs), rRNA-derived small RNAs (rsRNAs), and
YRNA-derived small RNAs (ysRNAs) [244]. This TRY-
RNA signature helps to differentiate between LC and
pulmonary tuberculosis, and thus possess diagnostic im-
plications for LC screening [244]. A recent study dem-
onstrated the potential of PD-L1 siRNA encapsulated
gold nanoparticles for the imaging and treatment of LC
[245]. These nanoparticles downregulate the expression
of PD-L1 in NSCLC cell lines and xenograft studies and
serve as photothermal agents for LC photothermal ther-
apy [245]. Thus, it demonstrates the theranostic applica-
tion of siRNAs in LC when combined with suitable
photothermal agent. KDM3A is lysine-specific demethy-
lase that increases the expression of DCLK1 by reducing
the methylation of H3K9me2. It was recently demon-
strated that bone marrow mesenchymal stem cell-
derived extracellular vesicles (BMSC-EV) encapsulated
let-7i miRNA decreases LC growth by suppressing the
KDM3A-DCLK1-FXYD3 axis [246]. This study estab-
lished KDM3A is a direct target of let-7i, and the high
expression of KDM3A and DCLK1 is associated with re-
duced expression of let-7i. In vivo BMSC-EV derived let-
7i downregulated the KDM3A, and decreased tumor
growth [246].
In addition, extracellular miRNAs also serve as diag-
nostic biomarkers for LC [247]. A study involving NSCL
C patients, patients with benign nodules, and healthy
controls demonstrated the utility of miR-520c-3p and
miR-1274b in the identification of NSCLC risk factors
[248]. The panel of these two-miRNA has the potential
to differentiate between NSCLC and benign nodules and
suggested the importance of extracellular miRNAs for
diagnostic utilization in NSCLC [248]. Similarly, another
recent study demonstrated the clinical significance of
circulating/serum exosomal miR-let-7e as a biomarker
for NSCLC metastasis [249]. Analysis of serum exo-
somes and tumor tissues from NSCLC patients demon-
strated that miR-let-7e was low, and suppressor of
variegation 3-9 homolog 2 (SUV39H2) was high in
NSCLC tissues and was associated with low OS. The ec-
topic overexpression of miR-let-7e or treatment with
serum-derived exosomes (miR-let-7e is high in serum-
derived exosomes) decreased cell viability, migration, in-
vasion, and delayed in vivo tumor growth by targeting
the SUV39H2-LSD1-CDH1 axis [249].
The therapeutic utility of miRNAs is also being inves-
tigated for SCLC. For example, low expression of
miRNA-195 has been observed in SCLC [250]. Low
miRNA-195 and high Rap2C were associated with low
OS in SCLC patients. Overexpression of miRNA-195
decreased the proliferation of SCLC cells through Bax
upregulation and Bcl2 downregulation. Further, this
study identified the binding site for miRNA-195 in the
Rap2C mRNA. Overexpression of miRNA-195 in SCLC
cell lines inhibited the activation of the MAPK pathway
by decreasing the expression of Rap2C and inducing
apoptosis [250].
Combination of small RNAs with chemotherapy in LC
Small RNA therapies substantially affect the growth of LC,
and thus targeted RNA combination therapies may be used
to improve therapeutic response. Several efforts have been
made to improve the utilization and formulations of RNA-
based cancer therapeutics, such as the use of nanoparticles
as a delivery vehicle [158, 251]. Interestingly, the
nanoparticles-based delivery systems not only protect the
small molecule RNAs from degradation but also facilitate
the evaluation of different combinational approaches to de-
velop effective LC therapies. Combination of chemotherapy
with anti-angiogenesis therapies is an attractive approach
against NSCLC [252, 253]. Integration of these two differ-
ent targeting strategies (anti-angiogenesis and chemother-
apy) is a promising approach to simultaneously target the
tumor vasculature and tumor cells. Two independent stud-
ies reported the utility of combining VEGF siRNA with two
different chemotherapeutic drugs [252, 253]. Zhang et al re-
ported the efficacy of coupling VEGF siRNA with gemcita-
bine using lipid-calcium-phosphate nanoparticles that
possess cell-specific targeting [252]. Compared to gemcita-
bine or VEGF siRNA alone, systemic administration of co-
targeting nanoparticles resulted in improved response in
subcutaneous as well as orthotopic mouse models of NSCL
C. The combination of VEGF siRNA and a gemcitabine-
induced significant decrease in tumor growth and tumor
microvessel density with minimal in-vivo toxicity [252].
Similarly, novel nanoparticles containing tripeptide lipids,
sucrose laurate, folate-PEG2000-DSPE were used to encap-
sulate paclitaxel and VEGF siRNA [253]. These nanoparti-
cles showed substantial specificity and anti-tumor activities
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in cell lines and mouse models of LC. In addition, these for-
mulations show improved bioavailability and led to a de-
crease in the effective therapy dose, thereby reducing
toxicity [253].
KRAS is the most common oncogenic mutation in
patients with NSCLC and is associated with recurrence
and poor survival [3, 254]. KRAS mutations are leading
to the constitutive activation of the KRAS, which sug-
gested the potential of mutant K-ras inhibition, may for
NSCLC treatment [255]. The approach combining
siRNA and miRNA provides innovative therapeutic
opportunities to combat oncogenic KRAS and other
oncogenic mutations in LC simultaneously. The lipid-
based polymeric nanoparticle containing the siRNA for
knocking-down oncogenic KRAS and overexpressing
miR-34a (p53-regulated tumor suppressor miRNA) has
shown promising therapeutic effects in lung cancer [33].
Additionally, this dual NP (miR-34a/siKras) in combin-
ation with cisplatin exhibited greater efficacy as com-
pared to cisplatin alone, suggesting that miR-34a/siKras
small RNA therapy can be combined with conventional
chemotherapeutic approaches to improve LC therapy
[33]. Furthermore, anti-mutant KRAS siRNA-loaded
hybrid nanoparticles (AKSLHNs) have been shown to
target the KRAS and inhibit the metastasis in a mouse
model of lung cancer [256].
Similarly, most of the anti-EGFR therapies aim to tar-
get the EGFR mutations, and the status of the EGFR
mutation determines the fate of such treatments [17,
257, 258]. In combination with TK inhibitors, siEGFR
induced apoptosis and reduced NSCLC cell growth
[259]. Recently, silencing of EGFR-TKs by a siRNA pool
and simultaneously delivering paclitaxel by using tumor-
targeted nanostructured lipid carriers resulted in en-
hanced tissue distribution and anticancer effects com-
pared with monotherapy or non-targeted therapy [260].
Studies have indicated that miRNAs contribute to the
resistance of TK inhibitor in EGFR mutated NSCLC tu-
mors. Expression of miR-146b-5p was higher in the
pleural discharge of treatment naïve patients as com-
pared to EGFR TK inhibitor-resistant patients. Overex-
pression of miR-146-5p in the resistant cells enhanced
their sensitivity to EGFR TK inhibitors. Similar observa-
tions were noticed in osimertinib resistant primary can-
cer cells in both EGFR-dependent and independent
manner [261]. Mechanistically, miR-146b-5p targets
interleukin 1 receptor-associated kinase 1 (IRAK1) by
downregulating NF-κB and related cytokine production
(IL-6 and IL-8). Thus, miR-146b-5p has the potential to
target IRAK1/NF-κB signaling, regulating EGFR TK in-
hibitor resistance, and may help combat resistance asso-
ciated with TK inhibitors [261]. MicroRNA-506 (miR-
506) functions as a tumor suppressor in multiple can-
cers, including LC [262–264]. Haque et al. reported
downregulation of miR-506-3p and Sonic Hedgehog
(SHH) signaling pathway in erlotinib resistant NSCLC
cell lines [265]. Overexpression of miR-506-3p inhibited
SHH signaling pathway and modulated epithelial to mes-
enchymal transition [265]. This study identified the SHH
pathway as a novel therapeutic target of miR-506-3p in
EGFR TK inhibitor-resistant EGFR mutated LC cell
lines.
A decreased expression of miR-3180-3p was noticed in
NSCLC cell lines and tumor tissues [266]. Exosome-
mediated delivery of miR-3180-3p decreased the prolif-
eration and metastasis of NSCLC cells through forkhead
box P4 (FOXP4). FOXP4 is an important target for
EGFR mutated LC and is involved in the regulation of
pulmonary gene expression. This suggests a possibility
of a miRNA-mediated targeting approach for FOXP4 as-
sociated pathways as a potential treatment option in LC
[267, 268]. miR-139-5p was shown to induce cisplatin
sensitization of NSCLC cells [269]. The expression of
miR-139-5p was downregulated in NSCLC compared to
adjacent normal tissue, and reduced expression was as-
sociated with cisplatin resistance. Overexpression of
miR-139-5p resulted in enhanced sensitivity to cisplatin,
inhibited cell proliferation, and induced apoptosis by
modulating the Homeobox protein Hox B2 (HOXB2)
and PI3K-AKT-caspase-3 axis [269].
As discussed in ASOs section, VEGF is a key mediator
of angiogenesis in most human tumors and is associated
with tumor relapse, metastasis, and poor prognosis of
NSCLC [270, 271]. Several targeted therapies for VEGF
and VEGF receptor (VEGFR), including antibodies and
small molecule inhibitors, have been evaluated in NSCL
C. Bevacizumab is a recombinant humanized monoclo-
nal antibody against VEGF-A that has been approved as
first-line therapy for unresectable, recurrent, locally ad-
vanced, or metastatic NSCLC [272]. Although combin-
ing the bevacizumab with chemotherapy improved the
overall survival in NSCLC, VEGF inhibitors have a short
half-life and numerous side effects [273–276]. Recently,
targeting of tumor angiogenesis via siVEGF was shown
to be an effective strategy in metastatic NSCLC [277].
Further, co-administration of siVEGF and etoposide
using cationic liposomes inhibited tumor growth and
metastasis more effectively than monotherapy [278].
Further, ASO against LINC00173.v1 reduced the growth
of lung squamous cell carcinoma and enhanced the sen-
sitivity to cisplatin in vivo via modulating the VEGFA
expression (for details, see ASO section) [196]. Ribonu-
cleotide reductase large subunit (RRM1) is a key enzyme
that plays a part in DNA synthesis, as it is required for
deoxyribonucleotide synthesis, and overexpression of
RRM1 is associated with LC [279, 280]. Adenoviral
vector-based short hairpin siRNA targeting the RRM1
gene (Ad-shRRM1)-mediated inhibition of RRM1
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augmented the sensitivity to gemcitabine, and combin-
ation treatment with Ad-shRRM1 and GEM exerted sig-
nificantly better inhibitory effects in LC compared to
monotherapy [281].
Bcl-2 is a well-known oncogene, is highly expressed in
the majority of SCLC, and contributes to chemotherapeu-
tic resistance [282]. G3139, a Bcl-2 ASO, along with pacli-
taxel was well-tolerated in chemo-refractory SCLC
patients [283]. Further, G3139, in combination with car-
boplatin and etoposide showed promising results in SCLC
patients [284]. However, a randomized phase II Study for
Bcl-2 ASOs (Oblimersen) in combination with carboplatin
and etoposide did not improve the clinical outcome in
advanced-stage SCLC patients [285]. Another oligo-
nucleotide against telomerase (Imetelstat) failed to im-
prove the progression-free survival in advanced NSCLC
patients [286]. Clusterin (Apolipoprotein J) encodes a
chaperone protein that is highly overexpressed in NSCLC
patients [287]. A Phase I study of custirsen (OGX-011), a
second-generation ASO to clusterin combined with cis-
platin and gemcitabine, showed a promising response in
patients with stage IIB/IV NSCLC [288].
AXL is overexpressed in tumor tissue of NSCLC pa-
tients and associated with poor survival [289]. Growth
arrest-specific protein 6 (GAS6) is a high-affinity ligand
of AXL. Gas6/AXL signaling pathway is associated with
tumor growth, metastasis, invasion, angiogenesis, drug
resistance, and immune regulation, making AXL a po-
tential target for several cancer therapies, including
NSCLC [290–293]. Recently a combination of an EGFR
targeting antibody (Cetuximab)-functionalized gelatin
nanoparticle (GAb) and covalently conjugated AXL
siRNA containing nanoconstruct (GAbsiAXL) showed
higher potential for intercellular internalization, im-
proved the siRNA stability, and increased the expression
of tumor suppressor P53 in drug-resistant NSCLC cells
[294]. Further, the combination of EGFR inhibitor (erlo-
tinib) and GAbsiAXL synergistically enhanced apoptosis
and inhibited cancer cell migration, demonstrating that
RNA-based inhibition of AXL in the combination of
chemotherapies may be beneficial in NSCLC [294].
Survivin is overexpressed in many cancers and regu-
lates the several pathways required for cancer stem cells
and tumor maintenance [295]. Thus, it is an exception-
ally attractive target for cancer therapeutics [295]. A
lipid-modified platinum-derivative-based nanoparticle
delivery system for survivin siRNA in combination with
cisplatin exhibited improved therapeutic efficacy in
chemo-resistant LC model, suggesting that RNA thera-
peutics against survivin is a promising approach [296].
The polyglutamate-derived brush polymer-based silen-
cing of survivin using si-RNA (PPGS/si-survivin
polyplex) combined with cisplatin exhibited synergistic
cytotoxic effects on drug-resistant LC cells [297].
Further, a pH based polyglutamate brush polymer
(DMA-mPEG-b-PG-g-spermine, DPPGS) containing the
dual siRNAs against MDR1 (siMDR1) and survivin (si-Sur-
vivin) enhanced sensitivity to the cisplatin. This combin-
ation appears to be a promising approach for overcoming
multi-drug resistant (MDR) NSCLC [298]. Interestingly,
survivin is also being investigated as a potential candidate
for immunotherapy and vaccine development [299].
Aprinocarsen, a first-generation ASO, is a phosphoro-
thioate oligonucleotide that targets human PKC-α
mRNA and inhibits PKC-α expression [300–302]. In
NSCLC, aprinocarsen has been extensively investigated
as a single anticancer agent or in combination with vari-
ous chemotherapeutic agents. In combination with
chemotherapy, aprinocarsen showed promising activity
in early phase studies, while higher toxicity was reported
in phase III trials (Table 1) [300, 301]. Similarly, in
SCLC, oblimersen failed to show benefit, either alone or
in combination with chemotherapy (Table 1) [285]. The
outcome of a phase II clinical trial, evaluating the effi-
cacy of carboplatin and pemetrexed plus either apator-
sen, a Hsp27 mRNA targeting ASO, or placebo showed
no additional toxicity; however, no improvement was
observed in treatment naïve patients with metastatic
nonsquamous NSCLC [306].
Besides therapy and diagnosis, miRNAs also play a role
in immunotherapy resistance [307]. Anti-PD1 immuno-
therapy, in combination with first-line chemotherapy,
improves the overall outcomes of LC; however, long-
term benefits of this regimen are frequently compro-
mised due to resistance to anti-PD1 [308–310]. Guyon
et al. recently developed a cellular model consisting of
T-cell and cell lines of different cancers (glioblastoma,
lung adenocarcinoma, breast cancer, and ovarian carcin-
oma) [307]. They used longitudinal blood samples from
anti-PD1 treated patients and LC mouse model and
demonstrated the enrichment of exosomal miRNA-4315
following anti-PD1 exposure to T-cells. The exposure of
cancer cell lines to exosomal miRNA-4315 induced
apoptosis resistance to chemotherapy via inhibition of
Bim (a pro-apoptotic protein) expression. The introduc-
tion of ABT263 (a BH3 mimetic) bypassed this resist-
ance. The analysis of patient blood samples suggested
that miRNA-4315 and cytochrome-c levels help define
the timeline to add ABT263 to enhance cell death and
overcome anti-PD1 resistance [307]. This study estab-
lished the role of exosomal miRNA-4315 for the stratifi-
cation of LC patients developing anti-PD1 resistance and
provide an alternative therapeutic option to utilize miR-
NAs for LC to modulate immunotherapy.
mRNA vaccines in LC
The primary objective of cancer vaccines is to elicit
or boost cancer-specific immunity. Tumor antigens
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trigger cancer immune response, and identification
and formulation of potential tumor antigens is a chal-
lenging task [51]. In the context of antigen formula-
tion, mRNA-based approaches provide a promising
way to design and synthesize antigens using intracellu-
lar machinery of the host/patient [37, 51]. DCs present
tumor antigenic peptides to cognate T-cell receptors
(TCRs) and induce tumor immunity and immuno-
logical memory [311]. The main targets of cancer vac-
cines include tumor-associated antigens (TAA) and
cancer neoantigens. The atypically expressed proteins
of tumors such as overexpression, different subcellular
localization, tumor specific expression (which are nor-
mally sequestered in immune-privileged sites or ex-
press during certain differentiation stages) compared
to normal tissues constitutes TAA. The recent success
of immune checkpoint blockade and initial success of
RNA-vaccine in Melanoma renewed the interest of re-
searchers in RNA-based cancer vaccines [37, 51, 157,
312]. RNA-based vaccines have emerged as a promis-
ing substitute for conventional vaccines. The recent
interim outcomes of a multicenter, open-label, dose-
escalation phase 1 clinical trial (NCT02410733) of an
intravenously administered liposomal RNA (RNA-
LPX) vaccine initiated by Shahin et al., demonstrated
the immunogenic potential of this mRNA-based vac-
cine in melanoma [51]. The cancer vaccine field is in
the developing phase, and only a few studies are avail-
able, particularly for LC. A clinical trial involving pa-
tients with stage IV NSCLC showed the benefits of
immunotherapy consisting of protamine-protected,
sequence-optimized mRNA (BI1361849 or CV9202)
encoding six NSCLC-associated antigens, including
New York Esophageal Squamous Cell Carcinoma-1
(NY-ESO-1), MAGE-C1, MAGE-C2, survivin, 5T4,
and Mucin-1), to induce targeted immune responses
in combination with local radiation treatment [313].
The treatment was well-tolerated with minor side ef-
fects. BI1361849 increased antigen-specific immune
responses in most patients, whereby antigen-specific
antibody levels and functional T cells were increased
by 80% and 40% of patients, respectively, supporting
further clinical investigation [313]. Similarly, another
phase I/IIa study also demonstrated that CV9201 was
well-tolerated and enhanced immune response in
stage IIIB/IV NSCLC patients [314]. These results sug-
gest the importance of mRNA-based immunotherapy
in combinations with immune checkpoint inhibitors in
NSCLC. Similarly, an ongoing phase I/II study
(NCT03164772) is evaluating the efficacy and safety of
mRNA Vaccine (BI 1361849) in the combination of
checkpoint inhibitors, anti-PD-L1 (durvalumab), and
anti-CTLA-4 (tremelimumab) for the treatment of
NSCLC.
Conclusion and future perspective of RNA
therapeutics
The utilization of RNA as a drug is a fundamentally
novel approach to conventional small molecule inhibi-
tors. The idea to translate RNA oligonucleotides' inhib-
ition mechanism into clinics almost took four decades to
become a reality. The recent FDA approvals of Givo-
siran, mRNA-1273-P301 (Moderna), and BNT162b1
(Pfizer-BioNTech) COVID-19 Vaccine [62, 315–317],
have ushered the wave of RNAi or mRNA-based therap-
ies into the mainstream of drug development. The out-
comes of RNA-based treatments also open a novel
direction of alternative therapeutic strategies to explore
RNA moieties for cancer therapy development. The ad-
vances in the understanding of siRNAs/miRNAs are ex-
pected to facilitate the development of more effective
‘combinational approaches’ through multi-targeting
properties of these small RNAs to treat cancer, as it is a
multi-gene-associated problem. The potential of RNA
therapies in precision genetics, like for the treatment of
hereditary transthyretin amyloidosis [61] and acute
intermittent porphyria [317], has raised enthusiasm for
similar applications in cancer therapies.
The new generation ASOs with GalNAc conjugation
(Givosiran) showed enhanced liver-specific delivery and
more than twenty-fold enhanced potency for RNase H1
dependent ASOs [44, 317], suggesting a possibility to de-
velop anticancer molecules to deal with organ-specific
metastases of LC or other cancers. The success of tar-
geted delivery and improved potency of ASOs provide a
strong motive to identify ligands/conjugates that can en-
hance the potency and targeting in other tissues. Target-
ing is a major problem in cancer drug development, so
Table 1 RNA based therapeutics in clinical trials in lung cancer
Drug combination Affected Pathway References
Custirsen + gemcitabine + cisplatin Clusterin [288]
Aprinocarsen + gemcitabine + cisplatin PKC-a [300, 303, 304]
Imetelstat + bevacizumab Telomerase [286]
LY2181308 + docetaxel Survivin [305]
Oblimersen + paclitaxel Bcl2 [283]
Oblimersen + carboplatin + etoposide Bcl2 [285]
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such modifications also provide a window to further
optimize the targeting of anticancer RNA drugs. How-
ever, RNA therapies can potentially reach the ‘golden-
age’ in some diseases, but before we reach the goal, there
are several challenges ahead, especially for cancer re-
search. Some of the major pitfalls are targeted delivery,
the stability of chemically synthesized RNAs compared
to in-vitro/in-vivo transcribed RNAs, modulation of im-
mune responses, and efficacy improvement. The field of
RNA nucleoside modifications or epitranscriptomics is
also under-investigated, including the identification of
oligonucleotides that can target RNA modifications and
the associated molecular pathways for the development
of cancer therapies. Nevertheless, some of the ASOs or
small RNAs did not proceed to the clinics, still putting
forward the potential and implications of the strategy to
further modify and optimize the RNA moieties for the
development of effective therapies for LC. The outcomes
of the studies also demonstrated the application and po-
tential of combining chemotherapeutic drugs and RNAi
tools or suggested the possibilities of coupling multiple
antisense molecules into a single nanoformulation, aim-
ing to expand the efficacies of LC therapies.
The recent outcomes of liposomal encapsulated
mRNA-based tumor vaccines have been promising in
melanoma (Lipo-MERIT trial, ClinicalTrials.gov identi-
fier NCT02410733) [51]. This vaccine provides durable
antigen-specific cytotoxic T-cell immune response alone
or in checkpoint inhibitor (PD1) treated patients and
provided vital evidence for the utilization of non-
mutated commonly shared tumor antigens for the devel-
opment of cancer vaccines. This initial success has raised
hopes for cancer vaccine development, and the focus
now is to identify tumor-associated antigens that can
serve as potential antigenic targets for the tumors pos-
sessing high mutational burdens like NSCLC and SCLC.
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